for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Indivior PLC

INDV.L

Latest Trade

51.66GBp

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

20.98

 - 

278.10

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
51.66
Open
--
Volume
--
3M AVG Volume
82.99
Today's High
--
Today's Low
--
52 Week High
278.10
52 Week Low
20.98
Shares Out (MIL)
730.73
Market Cap (MIL)
378.91
Forward P/E
3.22
Dividend (Yield %)
--

Next Event

Indivior PLC Capital Markets Day

Latest Developments

More

Indivior PLC Says Howard Pien Bought 50,000 Shares At $0.7359 Per Share On Aug 8

Indivior CEO Says Preparing For Trial On U.S. DoJ Indictment Into Marketing Of Suboxone

Indivior Says Q2 Pretax Profit Rises 14%

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Indivior PLC

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film (buprenorphine and naloxone), Suboxone Tablet (buprenorphine and naloxone), and Subutex Tablet (buprenorphine). Its other products include RBP-6000 in ATRIGEL, RBP-7000 risperidone monthly depot, Arbaclofen placarbil for alcohol use disorder (AUD), Intranasal naloxone for treatment of opioid overdose and RBP-8000 cocaine esterase for cocaine intoxication. Its RBP-6000 buprenorphine monthly depot is developed for the treatment of opioid use disorder. Its RBP-7000 risperidone monthly depot is developed for treatment of schizophrenia.

Industry

Biotechnology & Drugs

Contact Info

103-105 Bath Road

+44.1753.217800

http://indivior.com/

Executive Leadership

Howard Pien

Executive Chairman of the Board

Shaun Thaxter

Chief Executive Officer, Executive Director

Mark Crossley

Chief Financial and Operation Officer, Executive Director

Jon Fogle

Chief Human Resource Officer

Christian Heidbreder

Chief Scientific Officer

Key Stats

3.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.1K

2017

1.1K

2018

1.0K

2019(E)

0.7K
EPS (USD)

2016

0.340

2017

0.360

2018

0.370

2019(E)

0.200
Price To Earnings (TTM)
1.92
Price To Sales (TTM)
0.51
Price To Book (MRQ)
2.30
Price To Cash Flow (TTM)
1.71
Total Debt To Equity (MRQ)
143.90
LT Debt To Equity (MRQ)
139.02
Return on Investment (TTM)
31.44
Return on Equity (TTM)
16.13

Latest News

Indivior posts 14% rise in quarterly profit

Drugmaker Indivior Plc reported a 14% rise in quarterly profit on Wednesday, as its best-selling opioid addiction drug Suboxone lost market share to generic rivals at a slower pace, than the company's previous modelling had expected.

Indivior loses appeal to block generic Suboxone opioid treatments

A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.

Indivior loses appeal to block generic Suboxone opioid treatments

A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.

Indivior signs deal to sell schizophrenia drug in Canada

British drugmaker Indivior Plc on Thursday signed a licensing agreement with HLS Therapeutics Inc for the sale of its schizophrenia drug Perseris in Canada.

Indivior's Suboxone decline slower than feared as company bets on new opioid drug

Indivior Plc's best selling drug is losing market share slower than some analysts had predicted and its new drug is performing on target, lifting shares in the company despite its forecast of a possible loss this year.

Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptions

(This April 10 story refiles to fix scrambled syntax in paragraph five)

Indivior shares tank after U.S. indictment for illegal marketing

Shares of Indivior Plc sank 44 percent on Wednesday after the U.S. Justice Department accused the British drugmaker of illegally boosting prescriptions for the film version of its blockbuster opioid addiction treatment Suboxone.

U.S. indicts Indivior over Suboxone opioid treatment marketing

The U.S. Justice Department announced on Tuesday the indictment of Indivior Plc and a subsidiary on charges they engaged in an illegal scheme to boost prescriptions of the film version of its opioid addiction treatment Suboxone.

Indivior launches generic version of its Suboxone opioid drug

British drugmaker Indivior Plc said on Wednesday it had launched a copycat version of its blockbuster opioid addiction drug Suboxone in the United States, just one day after a court decision cleared the way for its rivals to market generic versions of it.

REFILE-Indivior launches generic version of opioid drug after losing court battle

Indivior Plc has launched a copycat of its blockbuster opioid addiction drug in the United States, the British drugmaker said on Wednesday, after losing a long-drawn court battle to prevent entry of generic rivals in its biggest market.

U.S. top court rejects bid to block Indivior opioid drug copycat

The U.S. Supreme Court dealt a blow to Indivior Plc on Tuesday, clearing the way for a copycat version of the British pharmaceutical firm's lucrative opioid addiction treatment Suboxone Film in a victory for India-based generic drug maker Dr. Reddy's Laboratories.

U.S. top court rejects bid to block Indivior opioid drug copycat

The U.S. Supreme Court dealt a blow to Indivior Plc on Tuesday, clearing the way for a copycat version of the British pharmaceutical firm's lucrative opioid addiction treatment Suboxone Film in a victory for India-based generic drug maker Dr. Reddy's Laboratories .

Indivior 2018 operating profit rises 51 pct on lower expenses

Drugmaker Indivior Plc reported a rise in full-year operating profit on Thursday, helped by lower operating expenses as it braces for the launch of cheaper copies of its blockbuster drug Suboxone after a long patent battle in U.S. courts.

Indivior loses U.S. district court battle, copycat launches imminent

Generic competitors to British drugmaker Indivior Plc's blockbuster opioid addiction treatment are on course to launch sales next week after the firm's attempt to stay a U.S. District court judgement was rejected.

UPDATE 2-UK Stocks-Factors to watch on Feb. 4

Britain's FTSE 100 index is seen opening 1 point higher at 7,021 on Monday, according to financial bookmakers, with FTSE 100 futures down 0.08 percent ahead of the cash market open.

Indivior temporarily stops rival Alvogen's generic launch

Indivior Plc said on Friday a U.S. district court had granted the British drugmaker a temporary restraining order, stopping rival Alvogen from launching cut-price versions of its blockbuster opioid addiction treatment.

Indivior temporarily stops rival Alvogen's generic launch

Indivior Plc said on Friday a U.S. district court had granted the British drugmaker a temporary restraining order, stopping rival Alvogen from launching cut-price version's of its blockbuster opioid addiction treatment.

Indivior plans cheaper opioid addiction drug if rivals launch copycats

Indivior Plc <INDV.L> said on Tuesday it could launch a cheaper version of its blockbuster opioid addiction treatment, Suboxone, if rivals release generic versions of the drug.

Indivior to launch cheaper opioid addiction drug; maintains forecast

British drugmaker Indivior Plc said on Tuesday it would launch a cheaper version of its blockbuster opioid addiction treatment drug, while maintaining its full-year profit and revenue forecast.

Indivior wins fresh hold on Dr. Reddy's Suboxone copy

Indivior Plc has secured another hold on the launch of a generic competitor to its best-selling opioid addiction drug in the United States, the London-listed company said on Wednesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up